Connect with us
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

News

Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

gbafNews28

– Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China – – Deciphera To Receive $20 Million Upfront Cash Payment, up to $185 Million in Potential Future Milestones and Royalties – – Deciphera Intends to Expand Ripretinib Development Program in Gastrointestinal Stromal Tumors (GIST) by Potentially Adding China Sites to the Ongoing Global Phase 3 INTRIGUE Study –

WALTHAM, Mass. and SHANGHAI, China, June 11, 2019 — Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd. (NASDAQ: ZLAB), a China and U.S.-based innovative biopharmaceutical company, today announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFRα. Under the terms of the agreement, Deciphera will receive an upfront cash payment of $20 million and will be eligible to receive up to $185 million in potential development and commercial milestone payments. In addition, Zai Lab would pay Deciphera royalties from low to high teens on annual net sales of ripretinib in Greater China. Zai Lab receives exclusive regional development and commercialization rights for ripretinib in Greater China. Zai Lab plans to leverage its regulatory and clinical expertise to lead development of ripretinib in this territory. Deciphera intends to expand the ongoing global Phase 3 INTRIGUE study, comparing ripretinib to sunitinib in second-line GIST patients, and is currently assessing the addition of clinical trial sites in China. “We believe Zai Lab is the ideal partner for the development and potential commercialization of ripretinib in Greater China,” said Steve Hoerter, President and Chief Executive Officer of Deciphera. “Zai Lab’s strong track record of rapidly progressing the development of innovative product candidates will be a major asset in accelerating the development of ripretinib in this area of the world. We are excited to be working with Zai Lab to potentially offer patients in Greater China what we believe is a much needed therapeutic option for the treatment of GIST.” “We are very pleased to enter into this exclusive agreement for ripretinib and look forward to partnering with Deciphera to potentially bring ripretinib to GIST patients in Greater China,” said Dr. Samantha Du, Chairman and Chief Executive Officer of Zai Lab. “Based on encouraging clinical data reported to-date, we believe ripretinib, if approved, could alter the treatment landscape for GIST patients. Ripretinib has strong clinical and commercial synergies with our existing pipeline of late stage gastrointestinal cancer programs. We are committed to working with Deciphera to expand the global effort to bring this important potential therapy to patients.” “Each year in China, approximately 30,000 patients are newly diagnosed with GIST, and an estimated 100,000 GIST patients are currently under treatment,” said Dr. Lin Shen, Head of the Chinese Society of Clinical Oncology GIST Expert Committee and Vice President of Clinical Oncology at Beijing Cancer Hospital. “There are significant unmet medical needs in GIST treatment especially for refractory patients after imatinib therapy. Based on preliminary data, I believe that ripretinib has a promising efficacy and safety profile that, if approved, could make it a good potential option for GIST patients.”

About Ripretinib

Ripretinib is an investigational KIT and PDGFRα kinase switch control inhibitor in clinical development for the treatment of KIT and/or PDGFRα-driven cancers, including GIST, systemic mastocytosis, or SM, and other cancers. Ripretinib was specifically designed to improve the treatment of GIST patients by inhibiting a broad spectrum of mutations in KIT and PDGFRα. Ripretinib is a KIT and PDGFRα inhibitor that blocks initiating and secondary KIT mutations in exons 9, 11, 13, 14, 17, and 18, involved in GIST as well as the primary D816V exon 17 mutation involved in SM. Ripretinib also inhibits primary PDGFRα mutations in exons 12, 14 and 18, including the exon 18 D842V mutation, involved in a subset of GIST.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals (NASDAQ: DCPH) is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. These investigational therapies comprise tumor-targeted agents designed to address therapeutic resistance causing mutations and immuno-targeted agents designed to control the activation of immunokinases that suppress critical immune system regulators, such as macrophages. We have used our platform to develop a diverse pipeline of tumor-targeted and immuno-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

About Zai Lab

Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and addressing unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide. Availability of Other Information About Deciphera Pharmaceuticals

Investors and others should note that Deciphera Pharmaceuticals communicates with its investors and the public using its company website (www.deciphera.com), including but not limited to investor presentations and scientific presentations, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Deciphera Pharmaceuticals posts on these channels and websites could be deemed to be material information. As a result, Deciphera Pharmaceuticals encourages investors, the media and others interested in Deciphera Pharmaceuticals to review the information that it posts on these channels, including Deciphera Pharmaceuticals’ investor relations website, on a regular basis. This list of channels may be updated from time to time on Deciphera Pharmaceuticals’ investor relations website and may include other social media channels than the ones described above. The contents of Deciphera Pharmaceuticals’ website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations regarding our license with Zai Lab, future development and potential commercialization of ripretinib in the Greater China territory and the potential payments we may receive therefrom, and the potential for ripretinib and our other drug candidates based on our kinase switch control inhibitor platform to provide clinical benefit and treat cancers such as GIST and other possible indications, enrollment for our INTRIGUE pivotal Phase 3 study, including, without limitation, the potential for and expectations with respect to opening China sites and enrolling China patients and estimates of China GIST patients. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to our ability to derive the benefits and mitigate the risks of any licensing transaction, the ability of our licensee to execute a successful development and potential commercialization of ripretinib in Greater China, our plans and ability to expand our INTRIGUE study, successfully open sites and enroll patients in China, the inherent uncertainty in estimating the number of target patient populations, including without limitation GIST patients in China, the delay of any current or planned clinical studies or the development of our drug candidates, including ripretinib, rebastinib, and DCC-3014, our advancement of multiple early-stage and later-stage efforts, our ability to successfully demonstrate the efficacy and safety of our drug candidates including in later-stage studies, the preclinical and clinical results for our drug candidates, which may not support further development of such drug candidates, our efforts to scale up and manage drug product manufacturing, our ability to implement commercial readiness, actions of regulatory agencies, any or all of which may affect the initiation, timing and progress of clinical studies and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Zai Lab Forward-Looking Statements

This press release contains statements about future expectations, plans and prospects for Zai Lab. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and are identified by words such as “anticipates”, “believes”, “expects”, “plan” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact nor are they guarantees or assurances of future performance. Forward-looking statements are based on Zai Lab’s expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) Zai Lab’s ability to obtain additional future funding, (2) Zai Lab’s results of clinical and pre-clinical development of its drug candidates, (3) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of Zai Lab’s drug candidates, (4) Zai Lab’s ability to generate revenue from its drug candidates, and (5) other factors discussed in Zai Lab’s Annual Report on Form 20-F for the fiscal year ended December 31, 2018 and its other filings with the Securities and Exchange Commission. Zai Lab anticipates that subsequent events and developments will cause Zai Lab’s expectations and assumptions to change and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing Zai Lab’s views as of any date subsequent to the date of this press release.

Contacts: Company: Christopher J. Morl, Chief Business Officer Deciphera Pharmaceuticals, LLC [email protected] 781-209-6418

Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc. [email protected] 781-906-1112

Media: Gina Nugent, The Yates Network [email protected] 617-460-3579

Zai Lab: Billy Cho, CFO +86 137 6151 2501 [email protected]

Media: Nancie Steinberg / Robert Flamm Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 318 / 364, [email protected] / [email protected]

Investors: Lee Roth Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 331, [email protected]

Primary Logo

News

Bearing Isolators Market 2020 – 2024: Post-Pandemic Industry Planning Structure | Technavio

gbafNews28

The bearing isolators market is expected to grow by USD 87.63 million during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the bearing isolators market in optimistic, probable, and pessimistic forecast scenarios.

The bearing isolators market will witness Neutral and Inferior impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavios pandemic-focused market research, market growth is likely to Decrease as compared to 2019.

Enterprises will go through Respond, Recover and Renew phases. Download free report sample

As the COVID-19 pandemic continues to spread, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through respond, recover and renew phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis and towards the Next Normal.

This post-pandemic business planning research will aid clients to:

  • Adjust their strategic planning to move ahead once business stability kicks in.
  • Build Resilience by making effective resource and investment choices for individual business units, products and service lines.
  • Conceptualize scenario-based planning to mitigate future crisis situations.

Download the Post-Pandemic Business Planning Structure. Click here

Key Considerations for Market Forecast:

  • Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
  • Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
  • Pre- as well as post-COVID-19 market estimates
  • Quarterly impact analysis and updates on market estimates

Gain instant access to 17,000+ market research reports by using

Technavio’s SUBSCRIPTION platformTop of Form

Major Three Bearing Isolators Market Participants:

Parker Hannifin Corp.

Parker Hannifin Corp. operates its business under diversified industrial and aerospace systems segments. The company offers non-contact, labyrinth designs bearing isolators that provide unsurpassed bearing protection for rotary shaft equipment. Some of the bearing isolators are LS-standard flanged isolator, LN-standard non-flanged, flush mount isolator, FN-360 for flooded oil level, and oil mist applications, non-flanged, among others.

Smiths Group Plc

Smiths Group Plc operates its business under five segments, which include John Crane, Smiths Detection, Flex-Tek, Smiths Interconnect, and Smiths Medical. The company offers Magnum D V8, Magnum P V7, and Magnum P V68 bearing isolators, under its subsidiary John Crane.

The Timken Co.

The Timken Co. has business operations under mobile industries and process industries segments. The company offers metallic isolators, non-metallic isolators glass-filled PTFE, and non-metallic isolators graphite-filled PTFE.

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Get report snapshot here to get detailed market share analysis of market participants during COVID-19 lockdown: https://www.technavio.com/report/ bearing isolators market-industry-analysis

Bearing Isolators Market 2020-2024: Segmentation

Bearing Isolators is segmented as below:

  • End-user
    • Oil and gas
    • Chemical processing and manufacturing
    • Mining and metal processing
    • Paper and pulp
    • Food and beverage
  • Material
    • Non-metallic bearing isolators
    • Metallic bearing isolators
  • Geography
    • North America
    • Europe
    • APAC
    • MEA
    • South America

The bearing isolators market is driven by the benefits of bearing isolators. In addition, other factors such as rising industrialization in APAC is expected to trigger the bearing isolators market toward witnessing a CAGR of over 1% during the forecast period.

Get more insights about the global trends impacting the future of bearing isolators market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR45155

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

Continue Reading

News

Mind Body Social Is Bringing the “W.O.W” to Virtual Wellness in October!

gbafNews28

The new normal has called us all to redefine our approach to lifes most basic needs and physical and mental fitness are more important than ever, as we aim to keep our lives in balance. As a response, Mind Body Social will be hosting over 30 events from October 12th “ 17th, featuring more than 30 top experts & instructors, in a festival of virtual activities that provide the ultimate wellness experience, aiming to connect the local community, LIVE from iconic locations throughout South Florida.

Powered by T-Mobile, W.O.W. SoFlo is a Week Of Wellness featuring workouts, yoga sessions, guided runs, meditations and dancing, LIVE from multiple iconic locations from Palm Beach county to Miami-Dade, including the Everglades, Las Olas, Little Havana and Miami Beach, among many others. The program kicks off Monday, Oct. 12th with various activities including a very special Zumba class by celebrity dancer and international instructor, Toni Costa from T-Mobiles flagship store on Lincoln Road. The grand finale will take place on Saturday, Oct 17th with one of South Floridas biggest virtual 5K to date.

The program is FREE for all to participate thanks to the support of Baptist Health, Publix, BODYARMOR, Florida Blue and the programs Presenting Sponsor, T-Mobile, who continues to show their support for a healthy, connected South Florida.

Some of the special guests and instructors joining W.O.W SoFlo include Frankie Ruiz, co-founder of the Life Time Miami Marathon, who has curated the running program and Nikki Sapp Spoelstra who will be hosting a meditation and discussion centered around family life.

In the face of unprecedented times, we felt that Mind Body Socials mission to provide wellness and wellbeing to our community was more necessary now, than ever. Unable to do any more in-person events, we had to pivot and find ways to connect and serve. W.O.W SoFlo is the evolution of what weve been doing virtually since March, and its just the beginning of this movement, said Mind Body Social co-founders Jose Antonio Hernandez and Luis Sanabria.

W.O.W SoFlo will also help raise money throughout the week for key partners, including The Everglades Foundation, Susan G. Komen and Miami Water Keeper.

Full schedule of events available at: www.WOWSoFlo.com

About MIND BODY SOCIAL:

Mind Body Social produces event series that provide everyday people with tools to live a healthier life. Everything is centered around the community, and its free to participants thanks to strategic alliances and partnerships with renowned brands such as Facebook, Ikea Miami and Avianca Airlines, among others. The annual Mothers May Wellness Series presented by Publix, received a national award in 2019, and the virtual event series alongside Baptist Health South Florida, recently reached 100,000 participants since March 2020. For more information and current projects visit www.mindbodysocialevents.com

Mind Body Social

Media Contact: Victoria Gomez

Email: [email protected]

Phone: 786-556-0772

Continue Reading

News

TrellisWare Announces Completion of Field Demonstrations for HMS Operational Test Risk Reduction and New Warrior Robust Enhanced Networking (WREN) Narrowband (WREN NB) Waveform

gbafNews28

TrellisWare Technologies, Inc. is leading the development and deployment of the next generation waveforms for the US Army. TrellisWare recently completed successful execution of two field demonstrations that show the continued advancement of Army communication capabilities.

First Field Demonstration “TSM Waveform

The first field demonstration was of the TSM„¢ waveform on all four Product Manager (PdM) Handheld, Manpack and Small Form Fit (HMS) Program of Record (PoR) radios forming a single interoperable TSM network that supports the Armys voice, data and Position Location Information (PLI) Concept of Operations (CONOPS). By collaborating with all of the platform vendors “ Collins Aerospace for the AN/PRC-162, L3Harris for the AN/PRC-158 and AN/PRC-163, and Thales Defense & Security (TDSI) for the AN/PRC-148C “ TrellisWare proved that a Software Defined Radio (SDR) based waveform can be deployed on existing Army platforms to bring new networking capabilities to the Armys toolset.

In addition, TrellisWare worked closely with Program Manager Tactical Radios (PM TR) and the US Army Combat Capabilities Development Command C5ISR (Command, Control, Computers, Communications, Cyber, Intelligence, Surveillance and Reconnaissance) to show that the TSM waveform can seamlessly support key Army systems, namely the Nett Warrior End User Device (EUD) and the Joint Battle Command-Platform (JBC-P).

As a result, the network that TrellisWare demonstrated was a system of systems representation of the PdM HMS Integrated Operational Test and Evaluation (IOT&E) test scheduled for early 2021. The success of the demonstration is a significant risk reduction for the PdM HMS IOT&E, an event that will influence full rate production of the PoR radios.

TrellisWare will continue collaborative efforts with PM TR and the platform vendors to demonstrate a Secret and Below (SAB) TSM capability that leverages the Warrior Robust Enhanced Networking (WREN) security specification.

Second Field Demonstration – WREN Narrowband

The second capstone field demonstration was for the WREN Narrowband (WREN NB) waveform, a new Mobile Ad-hoc Network (MANET) waveform developed by TrellisWare. The new WREN NB waveform represents the modernization of resilient long-range narrowband communications.

The WREN NB waveform is a fast frequency hopping narrowband waveform that is Electronic Counter-Countermeasures (ECCM) capable. It provides simultaneous voice, PLI, and Command and Control (C2) data in a single network of 250+ nodes; operates in VHF, UHF, and L-band frequencies; supports Multiple Independent Levels of Security (MILS); and is portable to the PoR Manpack and Handheld Leader Radios. The WREN NB waveform represents a new technological capability for the Army to operate in congested and contested environments and is planned for inclusion in their future Capability Set.

In this field demonstration, TrellisWare was able to show the WREN NB waveform operating on both the TDSI AN/PRC-148C and Collins AN/PRC-162 platforms. Simultaneous voice, PLI and data communications were shown in a multi-hop network topology. PLI and chat messages were exchanged using Nett Warrior EUDs, and a JBC-P system was used to view a Common Operational Picture (COP). “The Office of the Secretary of Defense (OSD) Spectrum Access Research and Development Program (SARDP) has afforded the Army the opportunity to add this modernized capability into our toolbox, said Herald Beljour, CIV US Army CCDC C5ISR. This coming fiscal year we will transition this waveform to PM TR, and we will continue to put this capability through its paces.”

TrellisWare is leading the development and fielding of scalable and resilient waveforms for the US Army, said Metin Bayram, president and CEO of TrellisWare. Our TSM waveform is already a key component of the Integrated Tactical Network (ITN) that scales to support an entire battalion. With the completion of WREN NB, TrellisWare is further enabling the Army with resilient communications for operations in congested and contested environments.

About TrellisWare Technologies, Inc.

TrellisWare Technologies, Inc. is a worldwide leader in highly advanced algorithms, waveforms, and communications systems that range from small form factor radio products to fully integrated solutions. Our TSM„¢ waveform is incorporated into a wide range of systems, including TrellisWare radios and trusted industry partner radios, as well as multiple government and commercial solutions. TrellisWare is delivering the next generation of communications for military and commercial markets When Nothing Else Works„¢. For more information on TrellisWares products and solutions, please visit www.trellisware.com.

Tina Bachman

Marketing Communications Manager

TrellisWare Technologies, Inc.

PH: +1 858-753-1603

[email protected]

Continue Reading
gbafNews28 gbafNews28
News2 hours ago

Bearing Isolators Market 2020 – 2024: Post-Pandemic Industry Planning Structure | Technavio

The bearing isolators market is expected to grow by USD 87.63 million during 2020-2024, according to Technavio. The report offers...

gbafNews28 gbafNews28
News2 hours ago

Mind Body Social Is Bringing the “W.O.W” to Virtual Wellness in October!

The new normal has called us all to redefine our approach to lifes most basic needs and physical and mental...

gbafNews28 gbafNews28
News2 hours ago

TrellisWare Announces Completion of Field Demonstrations for HMS Operational Test Risk Reduction and New Warrior Robust Enhanced Networking (WREN) Narrowband (WREN NB) Waveform

TrellisWare Technologies, Inc. is leading the development and deployment of the next generation waveforms for the US Army. TrellisWare recently...

gbafNews28 gbafNews28
News2 hours ago

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Intel Corporation Investors of Important September 28 Deadline in Securities Class Action – INTC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intel Corporation (NASDAQ: INTC) between...

gbafNews28 gbafNews28
News3 hours ago

AM Best Upgrades Issuer Credit Rating of United National Life Insurance Company of America

AM Best has upgraded the Long-Term Issuer Credit Rating (Long-Term ICR) to bbb+ from bbb and affirmed the Financial Strength...

gbafNews28 gbafNews28
News3 hours ago

AM Best Affirms Credit Ratings of Stewart Title Guaranty de México, S.A. de C.V.

AM Best has affirmed the Financial Strength Rating of A- (Excellent), the Long-Term Issuer Credit Rating of a- and the...

gbafNews28 gbafNews28
News3 hours ago

Aquila Resources Announces Election of Directors

Aquila Resources Inc. (TSX: AQA, OTCQB: AQARF) (Aquila or the Company) announces that the six nominees listed in the management...

gbafNews28 gbafNews28
News3 hours ago

Cambridge Semantics Appoints Brian D. Owen as Chief Executive Officer

Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announces the appointment of...

gbafNews28 gbafNews28
News3 hours ago

ZenGRC Confirms Industry Leadership with Three Badges on G2 Fall 2020 Grid Report for GRC Platforms

Reciprocity, the company behind ZenGRC, the industry-leading information security risk and compliance solution, today announced ZenGRC has earned three badges...

gbafNews28 gbafNews28
News3 hours ago

The LYCRA Company to Showcase Latest Technologies at Intertextile Shanghai

The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel industry, will exhibit its...